Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 70, Issue 4, 2011, Pages 576-582

  Greenberg, Jeffrey D ^a   Kremer, Joel M ^b   Curtis, Jeffrey R ^c   Hochberg, Marc C ^d   Reed, George ^e   Tsao, Peter ^f   Farkouh, Michael E ^g   Nasir, Adeel ^a   Setoguchi, Soko ^f   Solomon, Daniel H ^f  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c The University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g Clinical Trials Unit   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEATH; DOSE RESPONSE; DRUG USE; DRUG UTILIZATION; FEMALE; GENDER; HEART INFARCTION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; RISK REDUCTION; STROKE; TRANSIENT ISCHEMIC ATTACK;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 79952351318     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.129916     Document Type: Article

References (38)

1. Solomon DH, Goodson NJ, Katz JN, et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006;65:1608-12. (Pubitemid 44799673)
2. Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis:a population-based study. Arthritis Rheum 2005;52:722-32. (Pubitemid 40365093)
3. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107:1303-7. (Pubitemid 36314415)
4. del Rincón ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-45. (Pubitemid 34016192)
5. Wolfe F, Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum 2008;58:2612-21.
6. Del Rincón I, Williams K, Stern MP, et al. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003;48:1833-40. (Pubitemid 36828677)
7. Goodson NJ, Symmons DP, Scott DG, et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis:a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 2005;52:2293-9. (Pubitemid 41117412)
8. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002;46:862-73.
9. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43. (Pubitemid 30165206)
10. Ridker PM, Rifai N, Pfeffer M, et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000;101:2149-53. (Pubitemid 30253042)
11. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-26.
12. Hochberg MC, Lebwohl MG, Plevy SE, et al. The benefit/risk profile of TNF-blocking agents:findings of a consensus panel. Semin Arthritis Rheum 2005;34:819-36. (Pubitemid 40740207)
13. Gartlehner G, Hansen RA, Jonas BL, et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis:a systematic review and metaanalysis. J Rheumatol 2006;33:2398-408. (Pubitemid 46067817)
14. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001;19:163-96.
15. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006;24:83-6.
16. Popa C, Netea MG, Radstake T, et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005;64:303-5. (Pubitemid 40193632)
17. Tam LS, Tomlinson B, Chu TT, et al. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 2007;26:1495-8. (Pubitemid 47201685)
18. Hürlimann D, Forster A, Noll G, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002;106:2184-7. (Pubitemid 35222210)
19. Mäki-PetäjäKM, Hall FC, Booth AD, et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006;114:1185-92. (Pubitemid 44386483)
20. Del Porto F, LaganàB, Lai S, et al. Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology (Oxford) 2007;46:1111-15. (Pubitemid 47050613)
21. Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007;56:2905-12. (Pubitemid 47502736)
22. Solomon DH, Avorn J, Katz JN, et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:3790-8. (Pubitemid 44955879)
23. Suissa S, Bernatsky S, Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum 2006;55:531-6. (Pubitemid 44289870)
24. Jacobsson LT, Turesson C, Gülfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005;32:1213-18. (Pubitemid 40995372)
25. Carmona L, Descalzo MA, Perez-Pampin E, et al., BIODASER and EMECAR Groups. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007;66:880-5.
26. Kremer J. The CORRONA database. Ann Rheum Dis 2005;64 ( Suppl 4 ):iv37-41.
27. Kremer JM. The CORRONA database. Clin Exp Rheumatol 2005;23 (5 Suppl 39):S172-7.
28. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
29. Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes:randomised controlled trial. Lancet 2004;364:675-84. (Pubitemid 39140623)
30. Pincus T, Summey JA, Soraci SA, Jr, et al. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983;26:1346-53. (Pubitemid 14231480)
31. Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
32. Barath P, Fishbein MC, Cao J, et al. Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol 1990;65:297-302. (Pubitemid 20038909)
33. Herskowitz A, Choi S, Ansari AA, et al. Cytokine mRNA expression in postischemic/reperfused myocardium. Am J Pathol 1995;146:419-28.
34. Dixon WG, Symmons DP. What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. Ann Rheum Dis 2007;66:1132-6. (Pubitemid 47309726)
35. Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101:1767-72. (Pubitemid 30213096)
36. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, et al. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 2004;51:447-50. (Pubitemid 38725146)
37. Choi HK, Hernán MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis:a prospective study. Lancet 2002;359:1173-7. (Pubitemid 34304256)
38. Davis JM, III, Maradit Kremers H, Crowson CS, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis:a population-based cohort study. Arthritis Rheum 2007;56:820-30. (Pubitemid 46399429)